| Autor: |
Ayşe Serra Artan, Şafak Mirioğlu, Rabia Hacer Hocaoğlu, Kenan Turgutalp, Saide Elif Güllülü Boz, Necmi Eren, Mevlüt Tamer Dinçer, Sami Uzun, Gülizar Şahin, Sim Kutlay, Şimal Köksal Cevher, Hamad Dheir, Mürvet Yılmaz, Taner Baştürk, Erhan Tatar, İlhan Kurultak, Ramazan Öztürk, Hakkı Arıkan, Serap Yadigar, Onur Tunca, Kültigin Türkmen, Ömer Celal Elçioğlu, Bülent Kaya, Şebnem Karakan, Yavuz Ayar, Cuma Bülent Gül, Halil Yazıcı, Savaş Öztürk |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
BMC Nephrology, Vol 25, Iss 1, Pp 1-10 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1471-2369 |
| DOI: |
10.1186/s12882-024-03784-8 |
| Popis: |
Abstract Background We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort. Methods In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR). Secondary composite outcome was at least a 50% reduction in estimated glomerular filtration (eGFR), initiation of kidney replacement therapies, development of stage 5 chronic kidney disease, or death. Results Median age at diagnosis was 48 (IQR: 37–57) years, and 358 (64.2%) were male. Patients were followed for a median of 24 (IQR: 12–60) months. Calcineurin inhibitors (CNIs) with or without glucocorticoids were the most commonly used regimen (43.4%), followed by glucocorticoids and cyclophosphamide (GC-CYC) (39.6%), glucocorticoid monotherapy (25.8%), and rituximab (RTX) (9.1%). Overall remission rate was 66.1% (CR 26.7%, PR 39.4%), and 59 (10.6%) patients reached secondary composite outcome. Multivariate logistic regression showed that baseline eGFR (OR 1.011, 95% CI: 1.003–1.019, p = 0.007), serum albumin (OR 1.682, 95% CI: 1.269–2.231, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink